Crinetics Pharmaceuticals Inc Aktie News

Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effects Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor e...

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an aggregate of 54,475 restricted stock unit (“RSU”) awards to 20 new non-executive employees,...

SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Crinetics Pharmaceuticals (CRNX 27.92%) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpriced. The U.S. Food and Drug Administration (FDA) approval on Sept.

Crinetics Pharmaceuticals received FDA approval for PALSONIFY, the first daily oral therapy for adults with Acromegaly, addressing a large unmet need. The company has submitted a Marketing Authorization Application for paltusotine in the EU, with a CHMP opinion expected in the first half of 2026. Expansion opportunities include a phase 3 study for carcinoid syndrome and two phase 3 trials for a...

Shares of Crinetics Pharmaceuticals surged Friday after the Food and Drug Administration approved the company's acromegaly drug, Palsonify.

Crinetics Pharmaceuticals, Inc. - Special Call Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, President, CEO & Director Dana Pizzuti - Chief Medical & Development Officer Isabel Kalofonos - Chief Commercial Officer Tobin Schilke - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Joshua Schimmer - Can...

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in rapid, durable, and consistent biochemical control and reduced symptom burden Launch of lead product PALSONIFY marks a pivotal milestone for ...